Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + docetaxel in advanced NSCLC progressed on PD-(L)1 inhibitors
NCT06928389Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ivonescimab + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall Survival at 5 years. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06928389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928389.